Vutrisiran in Transthyretin Amyloidosis
In a broad population of patients with ATTR who were treated for up to 58 months, vutrisiran was well tolerated and had an acceptable safety profile, consistent with that previously reported for the HELIOS-A and HELIOS-B studies.
Authors
- Marianne T. Sweetser
- C. Kwok
- Ronald Witteles (ORCID: https://orcid.org/0000-0002-3043-1472)
- Mark Taylor (ORCID: https://orcid.org/0000-0003-1270-7209)
- Katherine L. Boyle
- Julian D. Gillmore (ORCID: https://orcid.org/0000-0001-6174-9232)
- Pablo García‐Pavía (ORCID: https://orcid.org/0000-0002-5470-2257)
- Isabel M. Conceição (ORCID: https://orcid.org/0000-0003-0934-9631)
- Caroline Morbach (ORCID: https://orcid.org/0000-0002-0920-6094)
- David Adams (ORCID: https://orcid.org/0000-0002-8722-4108)
- William B White
Institutions
- University of Connecticut (US)
- Alnylam Pharmaceuticals (United States) (US)
- Inserm (FR)
- Liverpool Hospital (AU)
- The Royal Free Hospital (GB)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hospital Universitario Puerta de Hierro Majadahonda (ES)
- Universitätsklinikum Würzburg (DE)
- Stanford Medicine (US)
- Hospital de Santa Maria (PT)
- Bicêtre Hospital (FR)
- University College London (GB)
- Stanford University (US)
Publication Details
- Journal
- JACC Advances
- Published
- 2025-08-22
- DOI
- https://doi.org/10.1016/j.jacadv.2025.102066
- Citations
- 1
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- Alnylam Pharmaceuticals